Veradermics (MANE) return on equity (ROE)

Return on equity · fiscal 2025
-48.8%

Veradermics (MANE) earned a return on equity of -48.8% in fiscal 2025 (the year ended December 31, 2025). That is 3.3 percentage points higher than the -52.1% of fiscal 2024. Figures as of 17 Nov 2026, 23:50 UTC, from Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-48.8%
Change on fiscal 2024
+3.3 pts
Highest on record
-48.8%fiscal 2025
Lowest on record
-120.2%fiscal 2023
Fiscal years on record
32023–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Veradermics return on equity (ROE), in more detail

Across the 3 fiscal years on record (2023–2025), the highest was -48.8% in fiscal 2025 and the lowest -120.2% in fiscal 2023.

History · 3 fiscal years

Return on equity by fiscal year

Veradermics return on equity (ROE), year by year

Veradermics (MANE) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-48.8% 3.3 pts up
2024-52.1% 68.0 pts up
2023-120.2%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Veradermics and comparable companies
CompanyReturn on equityFiscal year
Scholar Rock Holding SRRK-154.0%2025
Teleflex TFX-29.0%2025
Mirum Pharmaceuticals MIRM-7.4%2025
Veradermics MANE-48.8%2025
Grifols GRFS7.6%2025
Cogent Biosciences COGT-51.7%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on MANE

Veradermics, figure by figure

Veradermics (MANE) overview: price, valuation and scorecardAll health care companies by market value

Veradermics return on equity (ROE): questions and answers

What is Veradermics's return on equity?

Veradermics (MANE) earned a return on equity of -48.8% in fiscal 2025 (the year ended December 31, 2025). That is 3.3 percentage points higher than the -52.1% of fiscal 2024.

What are the highest and lowest return on equity figures on record for Veradermics?

Across the 3 fiscal years on record (2023–2025), the highest was -48.8% in fiscal 2025 and the lowest -120.2% in fiscal 2023.

How is Veradermics's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Veradermics (MANE) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/MANE/roe

Underlying data: Yahoo Finance.